Inari Medical to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI), a medical device company focused on treating venous diseases, announced its participation in two upcoming investor conferences. The events include the 2020 Wells Fargo Virtual Healthcare Conference on September 10 at 10:00 a.m. ET and the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16 at 5:00 p.m. ET. Interested parties can access a live and archived webcast through the Investor Relations section of Inari's website. The company specializes in developing minimally-invasive devices for thromboembolism treatment.

IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.

• The 2020 Wells Fargo Virtual Healthcare Conference, Thursday, September 10, 2020 at 10:00 a.m. Eastern Time
   
• The Morgan Stanley Virtual 18th Annual Global Healthcare Conference, Wednesday, September 16, 2020 at 5:00 p.m. Eastern Time     

Interested parties may access a live and archived webcast of the presentation on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

What investor conferences is Inari Medical attending in 2020?

Inari Medical is attending the 2020 Wells Fargo Virtual Healthcare Conference on September 10 and the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16.

What time are Inari Medical's conference presentations scheduled?

The presentations are scheduled for 10:00 a.m. ET on September 10 and 5:00 p.m. ET on September 16.

Where can I access Inari Medical's conference webcasts?

Webcasts can be accessed on the Investor Relations section of Inari Medical's website.

What is the focus of Inari Medical's products?

Inari Medical focuses on developing products to treat venous diseases and improve the quality of life for patients suffering from venous thromboembolism.

What devices has Inari Medical developed for treating blood clots?

Inari Medical has developed the ClotTriever and FlowTriever systems, designed for minimally-invasive thrombectomy procedures.